Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 14.51% is 55% below its 5-year average of 32.27%, near the low end of its 5-year range (13.49%–94.02%).
33.55% below its 12-month average of 21.84%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
14.51%
RETURN ON EQUITY (ROE) AVG TTM
21.84%
RETURN ON EQUITY (ROE) AVG 3Y
21.53%
RETURN ON EQUITY (ROE) AVG 5Y
32.27%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-33.55%
CURRENT VS 3Y AVG
-32.61%
CURRENT VS 5Y AVG
-55.04%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
12.21%
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+18.84%
vs the sector median at left
GE HealthCare Technologies Inc.
Market Cap
$33.01B
Return on Equity (ROE)
14.51%
TTM Avg
21.84%
3Y Avg
21.53%
5Y Avg
32.27%
Market Cap
$32.79B
Return on Equity (ROE)
-22.60%
TTM Avg
-10.46%
3Y Avg
-1.37%
5Y Avg
1.10%
Market Cap
$32.58B
Return on Equity (ROE)
23.13%
TTM Avg
23.30%
3Y Avg
22.33%
5Y Avg
21.49%
Market Cap
$34.20B
Return on Equity (ROE)
38.14%
TTM Avg
28.93%
3Y Avg
25.01%
5Y Avg
22.95%
Market Cap
$31.16B
Return on Equity (ROE)
4.43%
TTM Avg
8.42%
3Y Avg
11.86%
5Y Avg
16.52%
Market Cap
$31.11B
Return on Equity (ROE)
1.09%
TTM Avg
29.98%
3Y Avg
64.02%
5Y Avg
111.55%
Market Cap
$30.96B
Return on Equity (ROE)
83.10%
TTM Avg
66.19%
3Y Avg
56.82%
5Y Avg
52.60%
Market Cap
$30.22B
Return on Equity (ROE)
59.67%
TTM Avg
-187.43%
3Y Avg
134.89%
5Y Avg
51.69%
Market Cap
$29.95B
Return on Equity (ROE)
5.97%
TTM Avg
9.02%
3Y Avg
4.86%
5Y Avg
4.86%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $33.01B | 14.51% | 21.84% | 21.53% | 32.27% |
| Centene Corp. (CNC)vs › | $32.79B | -22.60% | -10.46% | -1.37% | 1.10% |
| ResMed Inc. (RMD)vs › | $32.58B | 23.13% | 23.30% | 22.33% | 21.49% |
| DexCom, Inc. (DXCM)vs › | $34.20B | 38.14% | 28.93% | 25.01% | 22.95% |
| Biogen Inc. (BIIB)vs › | $31.16B | 4.43% | 8.42% | 11.86% | 16.52% |
| Waters Corporation (WAT)vs › | $31.11B | 1.09% | 29.98% | 64.02% | 111.55% |
| Zoetis Inc. (ZTS)vs › | $30.96B | 83.10% | 66.19% | 56.82% | 52.60% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $30.22B | 59.67% | -187.43% | 134.89% | 51.69% |
| Medline Inc. (MDLN)vs › | $29.95B | 5.97% | 9.02% | 4.86% | 4.86% |
| Mettler-Toledo International Inc. (MTD)vs › | $28.80B | 7062.40% | -2178.82% | -341.14% | -117.12% |
ROE
14.5%
ROA
4.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 20.08% |
| 2024-12-31 | 23.59% |
| 2023-12-31 | 21.98% |
| 2022-12-31 | 20.48% |
| 2021-12-31 | 13.49% |
| 2020-12-31 | 94.02% |
| 2019-12-31 | 0.00% |
